fda approves first oral glp-1 obesity drug august 21 2025 Orforglipron, approved as Foundayo on April 1, 2026, adds another option for chronic weight management in adults with or overweight plus at least one weight-related condition. The clinical relevance FDA approves first oral GLP1

Price & Trust Transparency Score: D Invigors Price & Trust Transparency Score shows that while it checks the right boxes on paper, the overall experience is rather bare bones

This offers a compelling mechanistic rationale for their use in DR, suggesting they do not merely offer a generic anti-inflammatory benefit, but may directly intervene in the specific immunological events now known to perpetuate retinal damage

Wood and Graham, 1995), which are deeply involved in the initial steps of atherogenesis

Occasionally, some patients notice increased hair growth in areas they did not expect, which should be discussed with your provider

Older adults (there is reduced stomach acid production with age, and acid in the stomach is necessary to absorb vitamin B12)

People who achieve substantial weight loss (typically 10 to 15 kg) within the first 6 years of a type 2 diabetes diagnosis can sometimes come off all medication and meet remission criteria: HbA1c below 48 mmol/mol (6